Prevention of hepatocellular carcinoma

Annals of Hepatology

Volumn 9, Issue 2, 2010, Pages 120-132

  Kew, Michael C ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Aflatoxin; Cirrhosis; Hepatitis B virus; Hepatitis B virus vaccine; Hepatitis C virus; Iron overload

Indexed keywords

AFLATOXIN B1; CHLOROPHYLL; GLYCYRRHIZIC ACID; HEPATITIS B VACCINE; HEPATITIS C VACCINE; LAMIVUDINE; OLTIPRAZ; PEGINTERFERON; PLACEBO; POLYPHENOL; RIBAVIRIN; AFLATOXIN; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT;

ARTICLE; CANCER PREVENTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; FOOD CONTAMINATION; FOOD INTAKE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IRON OVERLOAD; LEAFY VEGETABLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOW DRUG DOSE; NONHUMAN; PATIENT COMPLIANCE; PRIMARY PREVENTION; SECONDARY PREVENTION; VIRUS TRANSMISSION; LIVER TUMOR; PREVENTIVE HEALTH SERVICE; REVIEW; RISK FACTOR;

AFLATOXINS; ANTICARCINOGENIC AGENTS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FOOD CONTAMINATION; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IRON OVERLOAD; LIVER NEOPLASMS; PREVENTIVE HEALTH SERVICES; PRIMARY PREVENTION; RISK FACTORS; SECONDARY PREVENTION;

EID: 77956631057     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31650-3     Document Type: Article

References (98)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1.0. IARC Cancer Base No. 5. International Agency for Research on Cancer: IARC Press, Lyon, 2001.
2. Bosch FX, Ribes J. The epidemiology of primary liver cancer: global epidemiology. In: Viruses and Cancer. Tabor E (ed.). Amsterdam: Elsevier; 2002, p. 1-16.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55: 74-108.
4. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
5. Yu MC, Yuan MJ, Govindarajan S, Ross SK. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 2000; 14: 703-9.
6. World Health Organization (WHO) (2004). Hepatitis vaccines. WklyEpidem Rev 79; 255-63.
7. Stevens CE, Szmuness W. Vertical transmission of hepatitis B and neonatal hepatitis B. In: Viruses and the Liver. Bianchi L, Gerok W, Sickinger K, Stalder GA (eds.). Lancaster, UK: MTP Press. 1980: 71-4
8. Botha JA, Ritchie MJJ, Dusheiko GM, Mouton HWK, Kew MC. Hepatitis B virus carrier state in Black children in Ovamboland: Role of perinatal and horizontal infection. Lancet 1984; 2: 1209-12.
9. Atkinson W, Mamborsky J, Mclntyre L, Wolfe S. Hepatitis B. In: Epidemiology and Prevention of Vaccine-preventable Diseases. 8th. Ed. Washington DC, WA: Public Health Foundation; 2005, p. 151-212.
10. Beasley RP, Hwang L-Y, Lin CC, Chien CS. Hepatocellular carcinoma and HBV: A prospective study of 22,707 men in Taiwan. Lancet 1981; 22: 1129-33.
11. International Agency for Research on Cancer. Hepatitis Viruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 59. Lyon, France: IARC Press; 1994.
12. Kew MC. Hepatitis C virus and hepatocellular carcinoma in developing and developed countries. Vir Hepatit Rev 1998; 4: 259-69.
13. Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, Tanaka E. Hepatocellular carcinoma: Recent trends in Japan. Gastroenterology 2004; 127: S17-S26.
14. Kew MC. The role of cirrhosis in hepatocarcinogenesis. In: Liver Cell Carcinoma. Bannasch P, Keppler D, Weber G. (eds.). Dordrecht: Kluwer Academic Publishers; 1989. p. 37-46.
15. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50.
16. Kew MC. Hepatocellular carcinoma. Molecular biology and genetics. In: Gastrointestinal Oncology. 2nd. Ed. Kelsen DP, Daly JM, Kern SE, Levin B, Tepper JE, Van Cutsem E (eds.). Philadelphia: Lippincott, Williams and Wilkins; 2008, p. 405-18.
17. Wild CP, Gong YY. Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis 2010; 31: 71-82.
18. Sudakin DL. Dietary aflatoxin exposure and chemopreven-tion of cancer: a clinical review. J Toxicol Clin Toxicol 2003; 41: 195-204.
19. Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liv Internal 2003; 23: 1-5.
20. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Tram-pisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and non-cirrhotic patients with hereditary hemochromatosis. N Engl J Med 1985; 313: 1256-62.
21. Francanzani AL, Conte D, Fraquelli M, Roncalli M, Bonelli N, Borzio F, Maraschi A, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron related chronic liver disease. Hepatology 2001; 33: 647-51.
22. Bothwell TH, Bradlow B. Siderosis in the Bantu: a combined histopathological and chaemical study. Arch Pathol 1960; 70: 279-92.
23. Gordeuk VR. African iron overload. Sem Hematol 2002; 39: 263-9
24. Isaacson C, Seftel HC, Keeley KJ, Bothwell TH. Siderosis in the Bantu: the relationship between iron overload and cirrhosis. J Lab Clin Med 1981; 58: 845-85
25. Mandishona E, MacPhail AP, Gordeuk VR, Kedda MA, Pater-son AC, Rouault TA, Kew MC. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology 1998; 27: 1563-6.
26. Asare GA, Paterson AC, Kew MC, Khan S, Mossanda KS. Iron-free neoplastic nodules and hepatocellular carcinoma without cirrhosis in Wistar rats fed a diet high in iron. J Pathol 2006; 208: 82-90
27. Yu SZ, Chen G. Blue-green algae toxins and liver cancer. China J Cancer Res 1994; 6: 9-17.
28. Zhou TL, Yu SZ. Laboratory study on the relationship between drinking water and hepatoma: Quantitative evaluation using GGT method. China J Prev Med 1990; 234: 203-5.
29. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005; 34(Suppl), S1-S3.
30. Chang MH. Changing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization. Liver Linternat 2003; 23; 309-14.
31. Chang M-H, Shau WY, Chen CJ, Wu TC, Kong NS, Liang DC, Hsu MH, et al. The effect of universal hepatitis B vaccination on hepatocellular carcinoma rates in boys and girls. JAMA 2000; 284: 3040-2.
32. Lee CL, Hsieh KS, Ko YC. Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination. Cancer Epidemiol Biomarkers Prev 2003; 12: 57-9.
33. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM. Lin SM. Chu HC, et al. Decreased incidence of hepatocellular carcino ma in hepatitis B vaccines: a 20 year follow-up. J Natl Cancer Inst 2009; 101: 1348-55.
34. Kane MA. Global control of primary hepatocellular carcinoma with hepatitis B vaccine: The contributions of research in Taiwan. Cancer Epidemiol Biomarkers Prev 2003; 12: 2-3.
35. World Health Organization (WHO) Hepatitis B Fact Sheet No. 204 (revised October 2000). 2000. Available at www.who.int.
36. Chang MH, Chen THH, Tsu, Wu TC, Kong S, Liang DC, Ni YH, et al. Prevention of hepatopcellular carcinoma: the effect and problems. Clin Cancer Res 2005; 11: 7953-7.
37. Prozesky OW, Stevens CE, Szmuness W, Rolka H, harley EJ, Kew MC, Scholtz JE, et al. Immune response to hepatitis B vaccine in newborns. J Infect 1983; 7 (Suppl): S53-S55.
38. PAHO (Pan American Health Organization). Health in the Americas. Washington, DC, PAHO 2002.
39. Chen D, Weis KF, Chun Q, Erickson C, Endres R, Lively CR, Osorio J, et al. Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis viruses. J Virol 1999; 75: 11630-40.
40. Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Litte-lier M, Lisowa W, Yusibov V, Mason HF. A plant-derived edible vaccine against hepatitis B virus. FASEB J 1999; 13: 1796-9.
41. Richter LJ, Thanavla Y, Arntzsen CJ, Mason HS. Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol 2000; 18: 1167-71.
42. Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 2004; 127: S294-S302.
43. Kew MC, Francois G, Lavanchy D, Margolis H, van Damme P, Grob P, Hallauer J, et al. Prevention of hepatitis C virus infection. J Med Virol 2004; 11: 198-205.
44. Kensler TW, Egner PA, Wang JB, Zhu YR, Zhang BC, Lu PX, Chen JG, et al. Chemoprevention of hepatocellular carcinoma in anatoxin endemic areas. Gastroenterology 2004; 127: S310-S318.
45. Turner PC, Sylla A, Gong YY, Diallo MS, Sutcliffe AE, Hall AJ, Wild CP. Reduction in exposure to carcinogenic anatoxins by post harvest intervention measures in west Africa: a community-based intervention study. Lancet 2005; 365: 1950-6.
46. Yu SZ. Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol 1995; 10: 674-82.
47. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, et al. Treatment of acute hepatitis C with interferon a-2a. N Engl J Med 2001; 345: 1452-7.
48. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80-8.
49. Nomura H, Dou S, Tanimoto H, Nagahama T, Kimura Y, Ha-tashi J, Ishibashi A, et al. Short-term interferon a therapy for acute hepatitis C: a randomized control trial. Hepatology 2004; 39: 1213-9.
50. Arbuthnot P, Carmona S, Ely A. Exploiting the RNA interference pathway to counter hepatitis B virus replication. Liv internal 2005; 25:9-15.
51. Prince AM, Whalen R, Brotman B. Successful nucleic acid-based immunization of new-born chimpanzees against hepatitis B virus. Vaccine 1997; 15: 916-9.
52. Michel ML, Mancini-Bourgine M. Therapeutic vaccination against chronic hepatitis B virus infection. J Clin Virol 2005; 34(Suppl. 1): S108-S114.
53. Dashwood R, Negishi T, Hayatsu H, Breinholt V, Hendriks J, Baily G. Chemopreventive properties of chlorophylls towards anatoxin B1: a review of the antimutagenicity asd anticarcinogenicity data in Rainbow trout. Mutation Res 1998; 399: 245-53.
54. Kamat JP, Boloor KK, Devasgayan TP. Chlorophyllin as an effective anti-oxidant against the membrane damage in vitro and ex vivo. Biochim Biophys Acta 2000; 1487: 113-27.
55. Morel F, Fardel O, Meyer DJ, Langouet S, Gilmore KS, Me-unier B, Tu CP, et al. Preferential increase of glutathiones-transferase class? transcripts in cultured human hepatocytes by phenobarbital, 3.methylcholanthrene and dithiolethiones. Cancer Res 1993; 53: 231-4.
56. Egner PA, Wang J-B, Zu YR, Yhang BC, Wu Y, Zhang QY, Qian GS, et al. Chlorophyllin intervention reduces afla-toxin-DNA adducts in individuals at high risk of liver cancer. Proc Natl Acad Sci USA 2001; 98: 14601-6.
57. Gupta E, Olepade Ol, Ratain MJ, Mick R, Baker TM, Berzin FK, Benson AB, et al. Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. Clin Cancer Res 1995; 1: 1133-8.
58. Itoh K, Wakabayashi N, Kotoh H, Ishii T, Iganashi, K, Enge JP, Yamamoto M, et al. Keapl represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the aminoterminal Nrf2 domain. Genes Dev 1999; 13: 76-86.
59. Langouet S, Coles B, Morel F, Becquemont L, Beaume P, Guengerich FP, Kettere B, et al. Inhibition of CYP1A2 and CYP3A4 by oltipraz results in the reduction of aflatoxin B1 metabolism in human hepatocytes in primary culture. Cancer Res 1995; 55: 5574-9.
60. Sofowora GG, Choo EF, Mayo G, Shyr Y.Wilkinson GRl. In vivo inhibition of human CYP2A2 activity by olipraz. Cancer Chemother Pharmacol 2001; 47: 505-9.
61. Kensler TW, He X, Otieno M, Eggner P, Jacobson LP, Chen B, Wang JS, et al. Oltipraz chemoprevention trial in Qi-dong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol Biomarkers Prey 1997; 6: 257-65.
62. Wang JS, Shen X, He X, Zhu YR, Zhang BC, Wang JB, Qian GS, et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst 1999; 91: 347-54.
63. Fahey JW, Zhang Y, Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci USA 1997; 94: 10367-72.
64. Kensler TW, Chen JG, Egner PA, Fahey JW, Jacobson LP, Stephenson KK, Ye L, et al. Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomised clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol Biomark Prey 2005; 14: 2605-13.
65. Niederau C, Fischer R, Purschel A, Stremmel W, Hassinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107-19.
66. Kew MC, Popper H. Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis 1984; 1: 59-67.
67. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593-602.
68. Tabor E. Interferon for preventing and treating hepatocellular carcinoma associated with hepatitis B and C viruses. DigLivDis 2003; 35: 297-305.
69. Soga K, Shihasaki K, Aoyagi Y. Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatogastroenterology 2005; 52: 1154-8.
70. Omata M, Yoshida H. Resolution of liver cirrhosis and prevention of hepatocellular carcinoma by interferon therapy against chronic hepatitis C. Scand J Gastroenterol 2003; Suppl 237: 47-51.
71. Ikeda K, Saitoh S, Kobayashi M, Suzuli Y, Suzuki F, Tsubota A, Arase Y, et al. Long-term interferon for one year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study. J Gastroenterol Hepatol 2001; 16: 406-15.
72. Singal AK, Singh A, Jaganmhohan S, Gutura P, Mummadi R, You YF, Sood GK. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 192-9.
73. Takimoto M, Ohkoshi S, Ichida T, Takeda Y, Namoto M, Asakura H, Nailo A, et al. Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinoge-nesis in patients with chronic hepatitis C. Dig Dis Sci 2002; 47: 170-76.
74. Craxi A, Camma C. Prevention of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 329-46.
75. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, et al. Interferon-induced biochemical response reduces hepatocarcinogensis in hepatitis C virus infection. J Med Virol 2007; 79: 1485-90.
76. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Ya-mazaki O, Shiomi S, et al. Effects of long-term postoperative interferon-a therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Ann Intern Med 2001; 134: 963-67.
77. Miyake Y, Takaki A, Iwasaki Y Yamamoto K. Meta-analysis: Interferon-a prevents the recurrence after curative treatment of hepatitis C virus-related hepatocelluar carcinoma. J Viral Hepat 2010; 17: 287-92.
78. Melen K, Keskinen P, Lehtonen A, Julkinen I. Interferon-induced gene expression and signalling in human hepatoma cell lines. J Hepatol 2000; 33: 764-72.
79. Yamashita Y, Koike K, Takaoki M, Matsuda S. Suppression of HBsAg production in PLC/PRF/5 human hepatoma cell line by interferons. Microbiol Immunol 1988; 32: 1119-26.
80. MacMahon BJ, Hoick P, Bulkow L, Snowball M. Serological and clinical outcomes in 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759-68.
81. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, et al. Hepatitis B e antigen and the risk for hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
82. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fuku-du M, Koida I, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by hepatitis B virus: A pilot study. Cancer 1998; 82: 827-35.
83. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon-a treatment in Chinese patients with chronic hepatitis B infection: The effect of hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 139-45.
84. Lok A. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004; 127: S303-9.
85. Lin SM, Yu ML, Lee CM, Chen RM, Sheen IS, Chu CM, Liaw YF. Interferon therapy in HBeAg-postive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 45-52.
86. Ikeda K, Kobayashi M, Saitoh S, Someya T, Hasaka T, Aku ta H, Suzuki Y, et al. Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcino genesis in patients with cirrhosis undergoing interferon therapy: long-term follow up of a pilot study. J. Gastroenterol. Hepatol. 2005; 20: 95-102.
87. Yang WF, Zhao W, Zong WD. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Vir Hepat 2009; 16: 265-71.
88. Sung JJ, Tsoi KK, Wong VW, Chan HL. Meta-analysis: Treatment of hepatitis B infection redices risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-77.
89. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee LZ, Nuen H, Tanwandee T, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
90. Yuen MF, Seto WK, Chow DH, Tsui K, Wong PK, Ngai VW, Wong BC, et al. Long-term lamivudine treatment decreases the risk of long-term complications of chronic hepatitis B infection even in patients with advanced liver disease. Antiviral Ther 2007; 12: 1295-303.
91. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kamada H, Omata M, Okita K, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173-84.
92. Abe N, Ebina T, Ishida N. Interferon induction by glycyrr-hizin and glycyrrhetinic acid in mice. Microbiol Immunol 1982; 26: 535-9.
93. Kimura M, Watanabe H, Abe T. Selective activation of ex-trathymic T cells in the liver by glycyrrhizin. Biotherapy 1992; 5: 167-76.
94. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, et al. The long-term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79: 1494-500.
95. van Rossum TG, Vulto AG, de Man RA, Brouwer JT, Scalm SW. Glycyrrhizin as a potential treatment for chronic hepatitis C: A double-blind, randomised, placebo-controlled phase 1/2 trial. Aliment Pharmacol Ther 1998; 12: 199-205.
96. Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 2002; 62 (Suppl 1): 94-100.
97. Tarao K, Takemiya S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, Tanabe H, et al. Relationship between the recurrence of hepatocellular carcinoma and serum aminotransferase levels in hepatectomised patients with hepatitis C virus-associated cirrhosis and hepatocellular carcinoma. Cancer 1997; 79: 688-94.
98. Tang L, Tang M, Luo H. Chemoprevention trial of green tea polyphenols in high-risk population of liver cancer: modulation of serum and urinary aflatoxin biomarkers. Cancer Epidemiol Biomarkers Prev 2003; 12: 1349.